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Background: The prevalence of Helicobacter pylori resistance to metronidazole and clarithro-
mycin is high in Indonesia. Moreover, the increasing levofloxacin resistance rates in the absence 
of bismuth treatment in Indonesia has led to the use of other antibiotics as alternative regimens. 
Methods: We determined the minimum inhibitory concentrations (MICs) of five alternative 
antibiotics for H. pylori (rifaximin, rifabutin, furazolidone, garenoxacin, and sitafloxacin) using 
the agar dilution method and assessed mutations associated with antibiotic resistance using 
next-generation sequencing. 
Result: Analysis of 106 strains isolated from 1039 adult dyspeptic patients revealed that 
none of the strains were furazolidone-resistant. All strains were also sensitive to rifabutin and 
sitafloxacin. In contrast, the rates of resistance to rifaximin and garenoxacin were high (38.9% 
and 6.7%, respectively). The strains isolated from patients on Java Island had the highest 
resistance rates to garenoxacin and rifaximin. In addition, the resistance was distributed evenly 
among the ethnic groups, ranging between 25.0% and 69.2%. Except for rifaximin, for which 
the resistance rate was 38.9%, the other four antibiotics could be successfully employed to 
eradicate levofloxacin- and metronidazole-resistant H. pylori infections in vitro. Interestingly, 
garenoxacin-sensitive strains were found in regions with high clarithromycin resistance rates 
such as Bali and Papua Islands. In contrast, rifaximin might not be considered as an alternative 
antibiotic in regions with high clarithromycin resistance. There was an inconsistent association 
between gyrA and gyrB mutations and garenoxacin resistance. We confirmed that the I837V 
(replacement of isoleucine at position 837 with valine), A2414T/V, Q2079K and K2068R were 
the predominant rpoB point mutations. There was an association between vacA genotypes of 
H. pylori and rifaximin resistance (P = 0.048). 
Conclusion: furazolidone-, rifabutin-, and sitafloxacin-based therapies might be considered as 
alternative regimens to eradicate H. pylori in Indonesia, including regions with high metroni-
dazole and clarithromycin resistance rates. Moreover, sitafloxacin but not garenoxacin should 
be considered for eradication of levofloxacin-resistant strains.
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Introduction
Helicobacter pylori eradication has led to a significant decrease in the incidence of 
gastric cancer and can prevent its progression.1,2 The H. pylori eradication regimens 
established in the Asia-Pacific region and three countries in East Asia (Japan, South 
Korea, and China) have been summarized in the recent guidelines.3–6 Nevertheless, 
resistance to clarithromycin, which is included in the first-line therapy for H. pylori, 
has recently emerged in several regions across the globe.7–10 In addition, resistance to 
alternative regimens including metronidazole was significantly associated with their 
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frequent use.9,11 Moreover, high levofloxacin resistance was 
reported in several countries in Asia, and this even reached 
a rate of up to 67%.9,11–15 Based on the Maastricht Consensus 
V, a suitable first-line regimen is considered to be effective 
against H. pylori if the cure rate is >90%,16 and thus, it can 
prevent secondary antibiotic resistance. However, further 
investigation is warranted to assess the antibiotic sensitivity 
of H. pylori to overcome the multiple treatment failures, 
with H. pylori eradication failure in >20% of cases, in 
specific countries to determine the best rescue treatment 
regimens.17
Indonesia, located in Southeast Asia, is the fourth most 
populous country in the world, with a total population of 
~260 million in 2017, which is composed of various ethnic 
groups. Java, Sumatra, Papua, Kalimantan, and Sulawesi 
Island are the five main islands, with half of the total popula-
tion living on Java Island. Similar to other regions in Indone-
sia, we previously reported high resistance to clarithromycin 
(21.4%) on Java Island, the rate of which is more than the 
limit of 15% recommended by the Maastricht consensus.18 
In addition, the resistance rates to metronidazole and levo-
floxacin in Indonesian H. pylori strains are high (46.8% 
and 31.2%, respectively). Importantly, the prevalence of H. 
pylori infection in Indonesians, particularly among the major 
ethnic group of Javanese, is low (2.4%),19 highlighting the 
difficulties in isolating strains and conducting clinical trials 
on H. pylori eradication in Indonesia. In addition, although 
dyspepsia is the fifth most common symptom in an inpa-
tient setting in Indonesia, the availability of gastrointestinal 
endoscopy is limited, and it is predominantly utilized on 
Java Island.20
Among the several antibiotics proposed as alternative 
regimens for H. pylori is furazolidone, a synthetic nitrofuran 
with broad-spectrum antimicrobial activity that blocks bacte-
rial metabolism by interfering with bacterial oxidoreductase 
activity.21–25 Furthermore, in a study, the sensitivity of H. 
pylori to rifabutin and the utility of rifabutin as a rescue 
regimen following treatment failure with other antibiotics 
were reported in >50% of the subjects.26 Rifabutin is an 
antituberculosis agent which acts on DNA-directed RNA 
polymerase and inhibits transcription in H. pylori.27–29 
Rifaximin is a semisynthetic derivate of rifamycin with anti-
microbial activities against a broad spectrum of organisms, 
including H. pylori, is not absorbed in the gastrointestinal 
tract, and associated with mutations in rpoB.30 Conversely, 
garenoxacin and sitafloxacin, two novel quinolones, were 
proposed to treat H. pylori-resistant strains harboring gyrA 
mutation.31 In this study, we examined the resistance profile of 
H. pylori to several antibiotics used as alternative regimens in 
a geographical area with a high prevalence of clarithromycin- 
and metronidazole-resistant H. pylori strains. Our findings 
suggest several potential regimens that might overcome the 
hurdle of clarithromycin and metronidazole resistance, and 
the results might be of value not only for Indonesia but also 
for countries worldwide. Furthermore, we identified several 
point mutations in H. pylori that might confer rifaximin 
resistance.
Materials and methods
Patients and H. pylori
This nationwide study included 1,039 adult dyspeptic patients 
who underwent endoscopic biopsy between August 2012 
and February 2016 in 18 cities on eight Indonesian islands. 
Among these 1,039 patients, 752 were reported in a previ-
ous study.18Gastric biopsy specimens of the remaining 287 
patients used in the current study (Figure 1) were obtained 
from the following regions: Cimacan (n=22) and Surabaya 
(n=22) on Java Island; Padang (n=33), Palembang (n=38), 
and Dolok Sanggul (n=47) on Sumatera Island; Gunungsitoli 
(n=32) on Nias Island; Kolaka (n=50) on Sulawesi Island; 
and Merauke (n=43) on Papua Island. There were 599 males 
(age range, 17–88 years; mean, 46.14±13.63 years) and 439 
females (age range, 14–80 years; mean, 47.79±14.4 years). 
Patients with bleeding due to esophageal varices, those with 
a history of partial gastric resection, and those with a history 
of successfully eradicated H. pylori infection were excluded. 
Figure 1 The chart showing the enrollment of patients in the current study.
Note: *One strain (Malang1) could not grow well, and hence, we excluded it from 
the study.
All enrolled patients
N=1,039
Reported in our
previous study
N=752
Successfully cultured
N=77
Successfully cultured
N=29
Analyzed in current
study
N=105*
Newly enrolled in
current study
N=287
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All procedures applied in this work complied with the ethical 
standards of the relevant national and institutional commit-
tees on human experimentation and with the Declaration of 
Helsinki of 1975, as revised in 2008 and 2013. Peptic ulcer 
disease was diagnosed by endoscopic examination, whereas 
the diagnosis of gastritis was based on histologic examina-
tion. The review board or the ethics committee of the follow-
ing institutions reviewed and approved the study protocol: Dr. 
Cipto Mangunkusumo Teaching Hospital (Jakarta, Indone-
sia), Dr. Soetomo Teaching Hospital (Surabaya, Indonesia), 
Dr. Wahidin Sudirohusodo Teaching Hospital (Makassar, 
Indonesia), and Oita University Faculty of Medicine (Yufu, 
Japan). All study participants agreed to follow the study 
protocol and provided written informed consent. For the 
participants who were <18 years old, the parents or legal 
guardian provided written informed consent.
H. pylori was isolated from homogenized antral biopsy 
specimens by inoculating onto selective agar plates and 
incubating the plates for up to 10 days in microaerophilic 
environment (10% O
2
, 5% CO
2
, and 85% N
2
) at 37°C. The 
colonies that grew were subcultured onto antibiotic-free 
Mueller–Hinton II agar (Beckton Dickinson, Franklin Lakes, 
NJ, USA) supplemented with 10% horse blood under the 
same microaerophilic conditions. H. pylori isolates were 
confirmed based on colony morphology and Gram staining 
as well as oxidase, catalase, and urease test results. The iso-
lates were stored in Brucella broth (Difco, Franklin Lakes, 
NJ, USA) supplemented with 10% dimethyl sulfoxide and 
10% horse serum at −80°C.
antibiotic susceptibility testing
The twofold agar dilution method was used to determine 
minimum inhibitory concentrations (MICs) of furazoli-
done (Tokyo Chemical Company, Tokyo, Japan), rifaximin 
(Tokyo Chemical Company), rifabutin (Sigma-Aldrich 
Co., St. Louis, MO, USA), garenoxacin (Sigma-Aldrich 
Co.), and sitafloxacin (Haoyuan Chemexpress, Shanghai, 
China) according to M07-A9 version of methods for dilu-
tion antimicrobial susceptibility test for bacteria that grow 
aerobically (approved standard, Clinical and Laboratory 
Standard Institute). Briefly, the isolates were subcultured on 
Mueller–Hinton II agar supplemented with 10% horse blood. 
The bacteria were diluted in Brucella broth and adjusted to 
be equivalent to a McFarland opacity standard of 0.5. The 
prepared bacterial suspension (1 µL) was then inoculated 
using 2 mm-pin inoculator (Tokken Inc. Chiba, Japan) on 
Mueller–Hinton II agar supplemented with 5% horse blood. 
The MICs were determined after a 72-hour incubation. An 
H. pylori strain from American Type Culture Collection 
(catalog # 43504) was used as the quality control. Resistance 
breakpoints were determined based on an MIC of >4 mg/L 
for furazolidone and rifaximin and >1 mg/L for rifabutin, 
garenoxacin, and sitafloxacin, as described previously.32–35 
The final concentrations of furazolidone and rifaximin ranged 
from 0.25 to 32 µg/mL, while those of rifabutin, garenoxacin, 
and sitafloxacin ranged from 0.064 to 8 µg/mL.
Detection of virulence factors and 
resistant strains
H. pylori DNA was extracted using the commercially avail-
able DNeasy® kit (Qiagen, Hilden, Germany) and stored at 
−20°C until further analysis. Data on the gyrA and gyrB 
mutations in H. pylori were available for the 752 patients 
who were reported in our previous publication.18 In addi-
tion, mutation analyses were performed for gyrA and gyrB 
mutation status in the remaining 287 specimens. Further-
more, next-generation sequencing (MiSeq next-generation 
sequencer; Illumina, San Diego, CA, USA) was used to 
analyze all specimens for full-length rpoB, oipA status (“on” 
or “off ”), and the presence of vacA (s1 or s2; m1 or m2; and 
i1, i2, or i3), iceA (iceA1 or iceA2), jhp0562, and b-(1,3)galT 
genotypes of the Indonesian strains. The BLAST algorithm 
implemented in the CLC Genomics Workbench software 
(ver. 11; Qiagen NV, Venlo, Netherlands) was used for the 
analysis. The sequences of hp0701, hp0501, hp1198, and 
hp0638 of the strain 26695 (GenBank accession number 
AE000511.1) were used as queries to obtain the gyrA, 
gyrB, rpoB, and oipA sequences, respectively, from the 
Indonesian next-generation sequencing data. The variants 
related to antibiotic resistance were predicted by comparing 
all the rpoB sequences of resistant strains and five random 
sensitive strains with the rpoB sequence of the strain 26695 
for rifaximin resistance and gyrA and gyrB for garenoxacin 
and sitafloxacin resistance. Briefly, after obtaining the rpoB, 
gyrA, and gyrB sequences and confirming the absence of 
insertions or deletions leading to frameshift mutations, 
the sequences were aligned at the codon level using the 
MAFFT software (http://mafft.cbrc.jp/alignment/server/). 
Subsequently, each codon of the resistant and sensitive 
strains was compared to the reference sequence using our 
original PERL script and confirmed by visual inspection. 
Variants found in both the resistant and the sensitive strains 
were considered as normal variants and were excluded from 
further analysis. Variants found in the resistant strains but 
not in the sensitive ones were considered as variants related 
to antibiotic resistance.
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statistical analyses
Discrete variables were analyzed by the chi-squared test, 
whereas interval/ratio variables were analyzed using Student’s 
t-test or the Mann–Whitney U test. P values of <0.05 were 
considered statistically significant. All statistical analyses 
were performed using the SPSS statistical software package 
version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Resistance of H. pylori to alternative 
antibiotics
Twenty-nine H. pylori strains were isolated from 287 patients 
including 1, 1, 10, 1, 7, and 9 strains from Surabaya, Palem-
bang, Dolok Sanggul, Gunungsitoli, Kolaka, and Merauke, 
respectively. No H. pylori strains could be isolated from the 
specimens obtained from the patients in Cimacan and Padang. 
We also reanalyzed the 77 strains that were assessed for their 
sensitivity to clarithromycin, amoxicillin, metronidazole, 
tetracycline, and levofloxacin in our previous study.18 How-
ever, one of these strains (Malang1) did not grow properly. 
 Therefore, a total of 105 strains were analyzed in the current 
study.
Overall, more than half of the strains (61/105, 58.1%) 
were sensitive to all five antibiotics examined in this study. 
Forty strains were resistant to rifaximin (38.9%; Table 1). In 
addition, the rate of garenoxacin resistance was 6.7% (7/105). 
In contrast, none of the examined strains exhibited resistance 
to furazolidone, rifabutin, or sitafloxacin. Four strains were 
resistant to two antibiotics. The rates of resistance to rifaxi-
min and garenoxacin were higher in males than in females 
(28/67 [42.4%] vs 12/38 [31.5%] and 5/67 [7.6%] vs 2/38 
[5.2%], respectively), although these differences were not 
statistically significant (P=0.28 and P=0.65, respectively). 
The antibiotic-resistant strains were more frequent among 
those older than 30 years of age, albeit in the absence of 
a significant association. Overall, 95, 1, and 9 antibiotic-
resistant strains were isolated from patients with chronic 
gastritis, gastric cancer, and peptic ulcer, respectively. The 
rate of garenoxacin resistance was higher in the patients with 
chronic gastritis than in those with peptic ulcer (6/95 [6.3%] 
vs 0/9 [0.0%]; P=0.001)
Rates of antibiotic resistance according 
to location and ethnicity
The rate of garenoxacin resistance was highest among the 
H. pylori strains obtained from Java Island compared to those 
from the other regions (15.4% vs 10.0%, 6.2%, and 4.7% 
from the Sumatera, Papua, and Sulawesi Island, respectively; 
Table 2). The garenoxacin resistance was not detected in any 
of the strains from Kalimantan, Timor, and Bali. In contrast, 
more than half of the strains isolated from the specimens of 
patients from Kalimantan, Sulawesi, and Bali Islands had 
rifaximin resistance (60.0%, 52.4%, and 50.0%, respec-
tively). Finally, the rate of rifaximin resistance was at least 
20% in all the study locations.
The analysis of the rates of antibiotic resistance according 
to ethnicity revealed that the garenoxacin resistance rate of 20% 
was higher in the strains isolated from the Chinese Indonesian 
patients than in those isolated from the Bataknese, Buginese, 
and Papuan patients (9.6%, 7.7%, and 6.2%, respectively; 
Table 3); however, this difference was not statistically signifi-
cant (P=0.44, P=0.33, and P=0.31, respectively). None of the 
Table 1 Rates of resistance to alternative antibiotics in Helicobacter pylori strains isolated in Indonesia
Characteristics N Resistance (%)
Furazolidone Sitafloxacin Garenoxacin Rifaximin Rifabutin
Total 105 0 (0.0) 0 (0.0) 7 (6.7) 40 (38.9) 0 (0.0)
Sex
Male 67 0 (0.0) 0 (0.0) 5 (7.6) 28 (42.4) 0 (0.0)
Female 38 0 (0.0) 0 (0.0) 2 (5.2) 12 (31.5) 0 (0.0)
age (years)
17–30 12 0 (0.0) 0 (0.0) 0 (0.0) 3 (25.0) 0 (0.0)
31–40 13 0 (0.0) 0 (0.0) 1 (7.6) 5 (38.4) 0 (0.0)
41–50 28 0 (0.0) 0 (0.0) 2 (7.1) 12 (42.8) 0 (0.0)
51–60 34 0 (0.0) 0 (0.0) 3 (8.8) 13 (38.2) 0 (0.0)
>60 18 0 (0.0) 0 (0.0) 1 (5.5) 6 (33.3) 0 (0.0)
clinical outcome
gastritis 95 0 (0.0) 0 (0.0) 6 (6.3) 34 (35.7) 0 (0.0)
PUD 9 0 (0.0) 0 (0.0) 0 (0.0) 3 (33.3) 0 (0.0)
cancer 1 0 (0.0) 0 (0.0) 1 (100) 1 (100) 0 (0.0)
Abbreviation: PUD, peptic ulcer disease.
Infection and Drug Resistance 2019:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
349
Miftahussurur et al
strains isolated from the Ambonese, Balinese, Dayak, Javanese, 
Minahasanese, and Timor patients exhibited garenoxacin 
resistance, indicating that the bacterial strains in the patients 
belonging to these ethnic groups were sensitive to furazolidone, 
rifabutin, garenoxacin, and sitafloxacin but not rifaximin. Only 
one strain from a Javanese patient (only one strain was isolated) 
was sensitive to all five antibiotics. Rifaximin resistance was 
distributed evenly among ethnic groups (Table 3), with the 
rates ranging between 25.0% and 69.2% (P=0.81). Within 
the ethnic groups with the highest prevalence of H. pylori in 
Indonesia,19 all the strains were resistant to garenoxacin and 
rifaximin, with the higher resistance rate to rifaximin observed 
in the Buginese patients compared with that in the Papuan and 
Bataknese patients (9/13 [69.2%] vs 6/16 [37.5%], P=0.01 and 
8/31 [25.8%], P=0.001, respectively).
comparison of alternative and standard 
antibiotic regimens
We determined the rates of resistance of the 76 H. pylori 
strains reported in our previous study14 to the five antibiotics 
and compared them with the rates of resistance to the standard 
antibiotics used for H. pylori infection (Table 4). Our findings 
Table 3 Prevalence of antibiotic resistance in Helicobacter pylori isolates based on ethnicity
Ethnicity Island N Resistance (%)
FUR SIT GAR RFX RIF
ambonese Java 4 0 (0.0) 0 (0.0) 0 (0.0) 2 (50.0) 0 (0.0)
Bataknese sumatera and Java 31 0 (0.0) 0 (0.0) 3 (9.6) 8 (25.8) 0 (0.0)
Balinese Bali 6 0 (0.0) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0)
Buginese sulawesi 13 0 (0.0) 0 (0.0) 1 (7.7) 9 (69.2) 0 (0.0)
chinese Java and Kalimantan 10 0 (0.0) 0 (0.0) 2 (20.0) 3 (30.0) 0 (0.0)
Dayak Kalimantan 2 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0)
Javanese Java 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Minahasanese sulawesi 8 0 (0.0) 0 (0.0) 0 (0.0) 2 (25.0) 0 (0.0)
Papuan Papua 16 0 (0.0) 0 (0.0) 1 (6.2) 6 (37.5) 0 (0.0)
Timor Timor 14 0 (0.0) 0 (0.0) 0 (0.0) 6 (42.8) 0 (0.0)
Abbreviations: FUR, furazolidone; GAR, garenoxacin; RFX, rifaximin; RIF, rifabutin; SIT, sitafloxacin.
Table 2 Rates of resistance to alternative antibiotics in Helicobacter pylori strains isolated in specific regions of Indonesia
Region N Resistance (%)
Furazolidone Sitafloxacin Garenoxacin Rifaximin Rifabutin
Bali 6 0 (0.0) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0)
Java 13 0 (0.0) 0 (0.0) 2 (15.4) 4 (30.7) 0 (0.0)
Kalimantan 5 0 (0.0) 0 (0.0) 0 (0.0) 3 (60.0) 0 (0.0)
Papua 16 0 (0.0) 0 (0.0) 1 (6.2) 6 (37.5) 0 (0.0)
sulawesi 21 0 (0.0) 0 (0.0) 1 (4.7) 11 (52.4) 0 (0.0)
sumateraa 30 0 (0.0) 0 (0.0) 3 (10.0) 7 (23.3) 0 (0.0)
Timor 14 0 (0.0) 0 (0.0) 0 (0.0) 6 (42.8) 0 (0.0)
Note: astrains obtained from patients from nias Island were combined with those of sumatera Island due to the low sample number.
above indicated that, except for rifaximin with a resistance 
rate of 35.5% (27/76), there was a possibility that the remain-
ing four antibiotics might overcome the high rate of resistance 
to levofloxacin and metronidazole. Interestingly, H. pylori 
in the regions with high rates of clarithromycin resistance, 
such as Bali and Papua Islands (1/6, 16.7% and 1/7, 14.3%, 
respectively), was still sensitive to garenoxacin, although 
this finding could be due to the low number of strains with 
clarithromycin resistance. In contrast, the isolate from Java 
Island with the highest rate of clarithromycin resistance also 
exhibited a high rate of rifaximin resistance. Thus, we suggest 
that rifaximin should not be considered as an alternative in 
areas with high clarithromycin resistance. Garenoxacin may 
combat H. pylori in regions with high amoxicillin resistance 
such as Papua Island (0.0% vs 14.3% of resistance rate for 
garenoxacin and amoxicillin, respectively) but not in regions 
with high tetracycline resistance such as Java Island (both 
15.4% of resistance rate) (Table 4).
To further analyze the associations among resistance rates 
of metronidazole, levofloxacin, garenoxacin, and rifaximin, 
we created a two-by-two table (Figure 2). Only seven strains 
(9.2%) exhibited resistance to both rifaximin and  levofloxacin. 
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 Furthermore, the percentage of the levofloxacin-resistant/
rifaximin-sensitive strains was lower than that of the levofloxacin-
sensitive/rifaximin-resistant strains (17/76 [22.4%] vs 20/76 
[26.3%]). In contrast, the percentage of the metronidazole-
resistant/rifaximin-sensitive strains was higher than that of the 
metronidazole-sensitive/rifaximin-resistant strains (23/76 [30.3%] 
vs 16/76 [21.1%]). Conversely, the percentages of the metronida-
zole-resistant/garenoxacin-sensitive and the levofloxacin-resistant/
garenoxacin-sensitive strains were higher than those of the 
metronidazole-sensitive/garenoxacin-resistant and levofloxacin-
sensitive/garenoxacin-resistant strains (19/76 [25.0%] and 30/76 
[39.5%] vs 0/76 [0.0%] and 1/76 [1.3%], respectively).
Mutations associated with garenoxacin 
resistance
We analyzed the gyrA and gyrB mutations from the two 
strains with high MICs for garenoxacin identified in the 
current study (Merauke20 and Kolaka72; Table 5) together 
Table 4 Comparison of the five alternative antibiotics with the standard regimens as reported by Miftahussurur et al18
Island n Resistant regimens (%)
CAM AMX MNZ TCN LVX FUR SIT GAR RFX RIF
Total 76 7 (9.1) 4 (5.2) 36 (46.7) 2 (2.6) 24 (31.2) 0 (0.0) 0 (0.0) 5 (6.5) 27 (35.5) 0 (0.0)
Bali 6 1 (16.7) 0 (0.0) 2 (33.3) 0 (0.0) 1 (16.6) 0 (0.0) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0)
Java 13 3 (23.0) 0 (0.0) 7 (46.1) 2 (15.4) 7 (53.8) 0 (0.0) 0 (0.0) 2 (15.4) 4 (30.7) 0 (0.0)
Kalimantan 5 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (60.0) 0 (0.0)
Papua 7 1 (14.3) 1 (14.3) 3 (42.9) 0 (0.0) 2 (28.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (28.5) 0 (0.0)
sulawesi 13 1 (7.7) 1 (7.7) 4 (30.8) 0 (0.0) 2 (15.4) 0 (0.0) 0 (0.0) 0 (0.0) 6 (46.1) 0 (0.0)
sumatera 18 1 (5.6) 1 (5.6) 16 (88.9) 0 (0.0) 8 (44.4) 0 (0.0) 0 (0.0) 3 (16.7) 3 (16.7) 0 (0.0)
Timor 14 0 (0.0) 1 (7.1) 3 (21.4) 0 (0.0) 3 (21.4) 0 (0.0) 0 (0.0) 0 (0.0) 6 (42.8) 0 (0.0)
Abbreviations: AMX, amoxicillin; CAM, clarithromycin; FUR, furazolidone; GAR, garenoxacin; LVX, levofloxacin; MNZ, metronidazole; RFX, rifaximin; RIF, rifabutin; SIT, 
sitafloxacin; TCN, tetracycline.
with those identified in our previous study.18 Four strains with 
the highest MICs for garenoxacin (2 mg/L) were associated 
with a high MIC for levofloxacin (>32 mg/L). In addition, 
three of these strains had an amino acid substitution at 
Asp91 or Asn87 in the GyrA, which were predominantly 
associated with the highest MICs for levofloxacin.18 However, 
the 13 garenoxacin-sensitive strains with low MIC values 
(<0.063–0.5 mg/L) were also associated with those muta-
tions, suggesting an inconsistent effect of these mutations. 
Moreover, none of the garenoxacin-resistant strains harbored 
a substitution at Arg484 or Ser479 of the gyrB. Finally, none 
of the strains harbored parC or parE, the two important genes 
associated with quinolone resistance in other bacteria.
Mutations associated with rifaximin 
resistance
We analyzed full-length rpoB from 40 rifaximin-resistant 
strains based on the next-generation sequencing data, with an 
Figure 2 The associations among rates of resistance to metronidazole, levofloxacin, garenoxacin, and rifaximin.
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average sequencing coverage ranging from 82.43x to 560.85x 
and a Q
30
 score percentage ranging from 80.59% to 96.31% 
(Table S1). Five random rifaximin-sensitive strains were 
used for comparison. Pairwise alignment identified that the 
garenoxacin-sensitive strains shared 95.7%–97.8% identity 
with the reference strain 26695. Using the strain 26695 and 
the garenoxacin-sensitive control strains, DNA sequence 
analysis of rpoB from all rifaximin-sensitive strains revealed 
intact reading frames that lacked nonsense mutations. Among 
all 2,890 codons of rpoB, 1,010 had non-synonymous substi-
tutions, indicating a change of nucleotide without a change 
in the amino acid (silent mutations). In contrast, majority of 
the rifaximin-resistant strains (39/40 [97.5%]) contained mis-
sense mutations (Table 6). We confirmed that the predominant 
point mutations of rpoB were the replacement of isoleucine 
at position 837 with valine amino acid (8/40 [20%]), alanine 
at position 2,414 with valine or threonine (8/40 [20%]), 
glutamine at position 2,079 with lysine (7/40 [17.5%]), and 
lysine at position 2,068 with arginine (7/40 [17.5%]).
Table 5 Mutations associated with quinolones
No. Strains gyrA mutation gyrB mutation MIC of LVX (mg/L) MIC of GAR (mg/L) MIC of SIT (mg/L)
1 Jayapura1 n87K none >32 0.25 0.063
2 Jayapura21 n87K none >32 0.125 0.063
3 Kupang2 D91n, a129T s479g 4 0.125 <0.063
4 Kupang11 D91Y none >32 0.25 <0.063
5 Kupang23 a129T s479g >32 0.125 <0.063
6 Kupang41 D91n R484K 8 0.5 <0.063
7 Malang1a D91n none 16 n.a. n.a.
8 Manado18 none none 8 0.5 <0.063
9 Manado20 D91Y none 8 0.25 <0.063
10 Medan3 n87I none >32 2 0.25
11 Medan10 none none 25 <0.063 <0.063
12 Medan15 R140K, D192n none >32 2 0.5
13 Medan17 D34n none 16 0.5 <0.063
14 Medan18 D91g, D161n none 4 <0.063 0.063
15 Medan22 D91n none >32 0.5 0.125
16 Medan23 D34Y, R140K none 4 0.063 <0.063
17 Medan30 D91n none >32 1 0.125
18 Pontianak50 D91g none >32 0.063 <0.063
19 surabaya71 D91n none >32 2 0.25
20 surabaya79 n87Y R484K >32 0.5 <0.063
21 surabaya137 n87K none >32 0.5 <0.063
22 surabaya151 n87K none >32 0.5 0.125
23 surabaya283 D91Y none >32 2 <0.063
24 surabaya304 D91g none >32 0.5 0.063
25 Merauke20b e103g none na 1 <0.063
26 Kolaka72b D91g none na 1 <0.063
Notes: an MIc >1 mg/L was used as a resistance breakpoint for levofloxacin, garenoxacin, and sitafloxacin. aOne of the previously isolated strains could not sustain growth. 
bThe new strains with high MIC of garenoxacin that were not reported in our previous study.
Abbreviation: GAR, garenoxacin; LVX, levofloxacin; MIC, minimum inhibitory concentration; na, not available; SIT, sitafloxacin.
Virulence factors and antibiotic resistance 
types
In addition to the data on virulence factors that we reported 
previously,18 we analyzed virulence factors in the 29 newly 
identified H. pylori strains including cagA, vacA, iceA, 
jhp0562/b-(1,3)galT, and oipA. There was an association 
between the vacA genotype of H. pylori with rifaximin 
resistance (P=0.048). The genotypes s2m1 and s1m1 of 
vacA tended to be more frequent in the garenoxacin-resistant 
strains compared with the vacA s1m2 and s2m2 genotypes 
(2/2 [100.0%], 32/74 [43.2%], 6/26 [23.1%], and 0/2 [0.0%], 
respectively; P=0.051). There were no significant associations 
between other virulence factors and antibiotic resistance.
nucleotide sequencing
The nucleotide sequences were deposited in the DDBJ 
under accession numbers LC420353–LC420380 (vacA), 
LC420381–LC420408 (oipA), LC420409–LC420436 
(jhp0562 and jhp0563), LC420437–LC420462 (iceA), 
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LC420463–LC420466 (gyrA and gyrB), and LC420467–
LC420511 (rpoB).
Discussion
The current study revealed that none of the H. pylori 
strains isolated from Indonesian patients were resistant 
Table 6 Mutations associated with rifaximin resistance
No. Strain name MIC (mg/L) rpoB mutation
1 surabaya47 4 S355Y, I741V, T2002M, Q2079K
2 Jayapura21 4 V1125I, A2454V
3 Jayapura06 8 L547F, K786R, I837V, A964T, V1275I, A1533S, P1623S, D1697N, G1908E, A2099T, S2640Y
4 Jakarta9 4 I64V, L295I, S355Y, V657I, T1023I, S1197A, Q2042R, K2068R
5 Kupang10 4 G523C, I832V, E877K, K1006E, E1528D, Q1666H, N1944S, A2255V, G2512S, S2619I, V2774M
6 Kupang23 4 L169S, S355H, A693T, I837V, K854R, L977I, I1351T, N1999H, K2068R, Q2079K, S2415N, I2481V, 
V2528L, P2679S, M2696T
7 Kupang26 4 L169A, S355H, I837V, L977I, N1999H, Q2079K, S2415N, A2472V, I2481V, V2528L, P2679S, M2696T
8 Kupang29 4 K42R, I748V, T773I, A958T, E969D, S986G, A1025V, V1052I, V1122I, A2414V, S2619I
9 Kupang30 4 S355H, S627N, I837V, A1025V, D1162N, K1165R, L1401I, R1711H, Q2079K, A2234T, D2380E
10 Kupang34 4 S355H, A732V, I837V, V955I, L977I, V1028A, N1999H, K2068R, Q2079K, S2415N, I2481V, V2528L, 
P2679s, M2696T
11 Bangli42 4 I141V, E163D, N642D, R954W, E996G, M1264I, E1407K, Y2275C, K2462E, V2469I, G2480R, T2539A
12 Bangli47 4 L314F, E1151K, I1190T, R1711H, K2068R, Y2326C, K2418Q, V2528L, T2536A, F2537L, K2538S, 
K2557R, V2561M, A2570T, S2734G
13 Bangli64 4 R63H, E162K, L295I, I336T, M667I, A735T, P816S, I837V, V867A, R973H, T975I, Q1010R, E1572Q, 
A1691V, A2346T, S2390G, G2491D, A2541V
14 Manado29 4 D255N, P259S, A1168V, A1181V, A1533T, L1765F, V1939I, A1950T, L2328I, R2694H, I2824V
15 Manado31 8 K307E, R984H, V1028A, A1533T, A2255V, Y2326C, A2494T
16 Merauke20 4 K786R, a964T, R2313h, g2512s
17 Merauke21 4 A1181V, G2180S, A2472T, P2545S, V2664M
18 Merauke27 4 I140V, A1533T, S1701N, A2505T, V2664M
19 Merauke37 4 s78P, P95h, M313l, K786R, a964T, l977F, e1014K, M1242I, D1379n, a1533s, g2180s, a2414T, 
R2477H, A2494T, I2730V
20 Kolaka72 4 R274I, S355Y, V538I, T635A, R1248H, G2403S, A2541, N2602D, R2641K, D2788G
21 Kolaka79 4 –
22 Kolaka96 4 R708K, L982S, E1161K, N1709D, E2382K, V2469I, R2477Y, V2528L, T2536A, F2537L, K2538S, 
K2557R, V2561M, R2882K
23 Kolaka98 4 P259S, A735T, S743A, I837V, T975S, A1025S, K1165R, D1379Y, K2068R, Q2079K, K2421R
24 Kolaka99 4 L295I, S355Y, A473V, M1175I, R1711H, Q2079K, A2454V, P2612S, S2675G
25 Makasar31 8 L295I, I336T, G615D, A735V, I837V, Q1010R, D1379Y, V1491I, H1985Y, V2237M, A2317V, D2380E, 
R2506c
26 Makasar45 4 E1161K, A2414V
27 Makasar52 4 E1161K, A2414V
28 Makasar55 4 P931s, a1643M, a1950T, K2068R, D2380e
29 Medan56 4 V303I, K1540N, A2414V, A2454V
30 Medan67 4 A497T, A958T, N1598H, T2002M, R2313C, A2414V
31 Medan75 4 I512V, M667I, A964V, T1402M, A2414V, E2599A, V2638I, S2791G
32 Padang42 4 H153Y, P931S, H1985Y, E2183K, A2414V, E2604G
33 Pontianak44 4 A487T, E969D, V1291I, A2255V, V2447I
34 Pontianak50 4 S355Y, S627N, E969K, R1563K, M1627I, A1676V, S1794N, N1999H, V2037I, D2449N, A2459T, 
T2533M, M2696T, e2859g
35 Pontianak5 4 V2802L
36 surabaya283 4 P259S, T440A, A497T, E1232D, N1944S, V2037I, I2428V, I2564V, Y2740H, K2889R
37 surabaya304 8 S78A, S355Y, K398R, V657I, E1486D, D2226S, L2328I, A2357V
38 Medan15 4 A473V, Q991R, E1059G, S1197A, K2068R
39 Medan22 32 I66V, L295I, S355Y, I586L, E655K, V657I, G1620S, A2541T, L2881I
40 Medan25 8 V52I, I66V, E106G, V657I, A756V, D2380E, K2482R
Note: s355Y means tyrosine replaced serine amino acid in the position 355.
Abbreviation: MIc, minimal inhibitory concentration.
to  furazolidone, suggesting that furazolidone might be 
considered as an alternative H. pylori treatment regimen 
in Indonesia, especially in regions with high prevalence 
of strains exhibiting dual resistance to clarithromycin and 
metronidazole.36 Our results are in agreement with those 
reported by a study from a neighboring country, Malaysia, 
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which also found that all the isolated strains were sensitive 
to furazolidone.37 Furazolidone use has been proposed in 
recent guidelines for H. pylori management in developing 
countries, due to its efficacy, low rate of primary bacterial 
resistance, and lack of alternative and low-cost therapies.38,39 
To improve the H. pylori cure rates, bismuth should be added 
to therapy. For example, the addition of bismuth to quadruple 
therapy including furazolidone has been successful in China, 
with cure rates reaching 92.26% with minimal side effects.40 
However, bismuth is unavailable in certain regions41 due to 
potential bismuth-associated carcinogenic effects, includ-
ing mutagenicity and genotoxicity in in vitro and animal 
models,42,43 and it was classified as a type III carcinogen for 
humans in 1997 by the International Agency on Research 
on Cancer. Furthermore, there are currently no standardized 
rescue therapies available for patients who fail the initial 
furazolidone-based treatment.
Our finding of all isolated strains exhibiting rifabutin sen-
sitivity provides support for rifabutin as a potential alternative 
antibiotic against H. pylori. The concentrations of rifabutin in 
the gastric juice were reported to be 10–17 times higher than 
in peripheral blood.44 The antibacterial activity of rifabutin, 
which is not affected by the low pH environment in the stom-
ach, is higher than that of rifampicin.27 Importantly, its target 
is different from that of clarithromycin. Therefore, its efficacy 
in strains with primary clarithromycin resistance, even in 
those who are also resistant to metronidazole, is high,45,46 
although the majority of the clinical trials that define these 
differences were conducted in Western countries. Nonethe-
less, the adverse effects of rifabutin such as myelotoxicity 
should be considered. Furthermore, the increased use of 
rifabutin in Indonesia, a country with high tuberculosis preva-
lence, might lead to rifabutin resistance of Mycobacterium 
tuberculosis. Several studies reported substantial in vitro 
cross-resistance to rifampicin, a main component of the tuber-
culosis therapy regimens, although rifabutin resistance in H. 
pylori in in vitro was rarely reported.28 A history of rifam-
picin treatment should be taken into consideration before 
prescribing rifabutin for H. pylori eradication to reduce the 
possibility of failure of tuberculosis treatment and H. pylori 
eradication. Importantly, rifabutin use in combination with 
clarithromycin should be avoided, based on evidence show-
ing the inhibition of rifabutin metabolism by clarithromycin 
in liver microsomes,47 which suggests that potential toxicity 
might arise with combination use.
Compared with the other fluoroquinolones, sitafloxacin 
is a more potent inhibitor of DNA gyrase and topoisomer-
ase IV, which play important roles in bacterial DNA repair, 
transcription, replication, and recombination.48 Sitafloxacin 
improves the efficacy of quinolone-based rescue therapy by 
virtue of its ability to eradicate H. pylori strains with gyrA 
mutations.49 However, limited access and availability are the 
main concerns regarding sitafloxacin. Currently, Japan and 
Thailand are the only countries that provide sitafloxacin in 
their health care system, and clinical trials for sitafloxacin 
are underway in Western countries.50 In contrast, although 
garenoxacin was also reported to eradicate H. pylori strains 
with gyrA mutations,51 there were several strains that were 
resistant to this antibiotic in the current study. Interestingly, 
the MIC value of levofloxacin was not associated with 
MIC value of garenoxacin. For example, although all seven 
garenoxacin-resistant strains exhibited the highest MICs 
for levofloxacin (>32 mg/L), all ten strains with the high-
est levofloxacin MIC were sensitive to garenoxacin. The 
lower antibacterial activity of garenoxacin against H. pylori 
compared with that of sitafloxacin might be associated with 
the high affinity of sitafloxacin to DNA gyrase.52 Due to 
high levofloxacin resistance rates in Indonesia, our finding 
should be instrumental in formulating second-line regimen 
guidelines to eradicate H. pylori.
One study found that double mutations in gyrA were 
associated with a sevenfold increase in sitafloxacin MIC com-
pared with the pretreatment MICs and that double mutations 
in gyrA, including the mutations at Asp91 and Asn87, were 
associated with eradication failure.53 We found that double 
mutations were not associated with an increase in the MIC of 
sitafloxacin, although none of the strains harbored both Asp91 
and Asn87 mutations. Similar to sitafloxacin, none of the 
single or double mutations in GyrA or GyrB were associated 
with garenoxacin resistance. Although parC and parE are 
important genes associated with quinolone resistance, none 
of the isolated H. pylori strains exhibited the presence of/
expressed these genes, as previously described.54 Our results 
suggest that genes other than gyrA or gyrB were associated 
with resistance to sitafloxacin and garenoxacin, which should 
be investigated in future studies.
Among the several alternative drugs tested in the current 
study, the rate of resistance was highest to rifaximin; this 
finding is in agreement with a previous study showing that 
rifaximin-based triple therapy did not achieve acceptable H. 
pylori cure rates.55,56 However, rifaximin is a promising H. 
pylori drug due to poor absorbance in the blood, which can 
minimize adverse effects, and its higher bioavailability in 
the gastrointestinal tract than that of other antibiotics.57 The 
poor eradication rates might be due to a failure in achieving 
sufficient therapeutic concentrations under and within the 
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gastric mucosal layer, which is a frequent site of H. pylori 
colonization.58 Therefore, well-designed clinical trials are 
necessary to evaluate rifaximin efficacy against H. pylori, 
including high-dose regimens of longer duration, additional 
bioadhesive formulations, and combinations with mucolytic 
agents for persistent coverage of the gastric mucosa.58
Although rpoB mutations were reported to play a role 
in rifaximin resistance in other bacteria such as Escherichia 
coli,59 Clostridium difficile,60,61 Staphylococcus,62 and M. 
tuberculosis,63 only one study found an association between 
codons 524–545 and 585 of rpoB with rifabutin resistance in 
H. pylori.30 In the current study, we found numerous missense 
mutations in rpoB of rifaximin-resistant strains, including 
novel and predominant mutations: 837I, 2414A, 2079K, 
and 2068K. Although the mechanism remains unclear, the 
risk for horizontal transmission of the rpoB mutations is 
lower than that of a resistance gene located on a plasmid or 
transposon; however, certain yet-to-be determined conditions 
and improper prescription or usage of antibiotic could still 
facilitate the rapid transmission of such mutations.62 Strict 
control should be practiced to prevent rifaximin failure in 
H. pylori eradication.
The major limitation of this study was the relatively small 
number of samples, and when we divided the samples based 
on regions, it yielded very low sample number in each region. 
Therefore, it may be difficult to represent H. pylori strains 
in whole Indonesia. Further study with a bigger sample size 
is necessary. However, these samples, obtained from 1,039 
endoscopic patients, comprised the biggest cohort of H. 
pylori strains isolated in Indonesia thus far. Indonesia is a 
wide country and consists of many ethnic groups. Among 
those, some ethnic groups had a much higher prevalence of H. 
pylori infection than the others; however, the overall gastric 
cancer risk in Indonesia is low, suggesting that Indonesia may 
become the best example for Asian enigma similar to South 
Asia. In addition, only a fraction of the genomic changes that 
were related to drug resistance, among a total of 1,600 genes 
of H. pylori, were examined in the current study. Although 
sitafloxacin is a potent drug for H. pylori, it has not been 
approved by the Indonesian National Agency of Drug and 
Food Control. Thus, sitafloxacin-based regimens cannot be 
currently prescribed in Indonesia.
Conclusion
Furazolidone-, rifabutin-, and sitafloxacin-based therapies 
should be considered as alternative regimens to eradicate 
H. pylori in Indonesia, including regions with high rates 
of metronidazole and clarithromycin resistance. Moreover, 
 sitafloxacin but not garenoxacin could inhibit the levofloxa-
cin-resistant H. pylori strains.
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Table S1 Mutations associated with rifaximin resistance
No. Strain ID Average  
coverage
Q30  
percentage
Rifaximin
1 Manado1 326.27 91.21 s
2 surabaya71 346.57 90.99 s
3 surabaya47 264.51 88.23 R
4 surabaya68 408.21 91.31 s
5 surabaya69 504.26 88.53 s
6 surabaya71 560.21 88.06 s
7 surabaya79 554.35 94.39 s
8 Jayapura1 570.45 95.95 s
9 Jayapura3 560.85 96.31 s
10 Jayapura6 589.56 95.97 R
11 Jayapura8 231.21 84.54 s
12 Jayapura15 489.67 96.36 s
13 Jayapura16 509.21 95.14 s
14 Jayapura21 502.21 96.49 R
15 Jakarta9 115.74 91.23 R
16 Medan17 142.34 80.59 s
17 Medan23 166.24 90.67 s
18 Medan27 91.58 80.76 s
19 Medan3 93.57 80.88 s
20 Medan10 85.96 80.44 s
21 Medan11 278.2 87.68 s
22 Medan15 260.45 80.59 R
23 Medan19 176.28 83.32 s
24 Medan20 164.28 82.27 s
25 Medan22 115.51 82.74 R
26 Medan23 264.07 81.06 s
27 Medan25 219.52 80.97 R
28 Medan28 169.54 80.8 s
29 Medan30 237.04 80.42 s
30 Makasar31 87.65 81.19 R
31 Makasar45 156.35 89.51 R
32 Makasar47 85.35 80.68 s
33 Makasar52 87.07 83.13 R
34 Makasar55 89.29 83.49 R
35 Makasar56 82.43 82.46 s
36 Pontianak63 82.77 88.97 s
37 Pontianak75 85.13 86.89 R
38 Pontianak20 191.58 89.57 s
39 Pontianak44 128.24 89.45 R
40 Pontianak50 99.51 91.01 R
41 Manado5 171.08 89.76 s
42 Manado18 136.04 90.18 s
43 Manado20 110.47 87.37 s
44 Manado26 151.85 86.67 s
45 Manado28 175.98 93.44 s
46 Manado29 90.53 93.63 R
47 Manado31 102.87 93.18 R
48 Kupang2 156.23 82.79 s
49 Kupang5 132.2 85.25 s
50 Kupang6 120.2 83.27 s
51 Kupang10 105.54 82.16 R
52 Kupang11 196.38 80.2 s
53 Kupang15 192.96 82.36 s
No. Strain ID Average  
coverage
Q30  
percentage
Rifaximin
54 Kupang23 125.05 84.94 R
55 Kupang26 98.87 89.29 R
56 Kupang28 146.88 86.58 s
57 Kupang29 144.7 81.55 R
58 Kupang30 85.85 85.47 R
59 Kupang33 158.02 83.55 s
60 Kupang34 238.16 87.82 R
61 Kupang35 240.73 85.3 s
62 Kupang41 112.69 85.57 s
63 Kupang42 86.98 81.43 R
64 Kupang47 142.12 85.5 R
65 Kupang64 171.52 82.59 R
66 Kupang73 134.33 88.07 s
67 Kupang83 152.03 85.08 s
68 Medan18 201.24 89.67 s
69 Medan31 162.6 90.39 s
70 Medan32 264.33 88.11 s
71 Medan33 368.99 86.63 s
72 nias9 123.05 84.92 s
73 Medan36 97.32 84.74 s
74 Medan37 95.96 85.43 s
75 Medan40 125.98 85.11 s
76 Medan49 163.37 83.54 s
77 Medan50 146.38 83.51 s
78 Medan56 192.02 83.51 R
79 Medan67 223.14 85.69 R
80 Medan68 137.93 84.11 s
81 Medan73 224.19 83.87 s
82 Medan75 194.47 83.86 R
83 Padang42 157.75 88.29 R
84 surabaya106 84.06 80.06 s
85 surabaya137 104.09 86.49 s
86 surabaya151 96.79 82.68 s
87 surabaya192 106.55 85.02 s
88 surabaya283 107.28 87.04 R
89 surabaya304 112.26 86.21 R
90 Merauke3 243.44 85.05 s
91 Merauke5 219.32 84.41 s
92 Merauke7 225.09 83.16 s
93 Merauke8 269.32 86.05 s
94 Merauke12 191.03 85.7 s
95 Merauke20 145.23 88.24 R
96 Merauke21 338.84 87.53 R
97 Merauke27 185.99 80.84 R
98 Merauke37 304.88 86.56 R
99 Kolaka56 219.48 85.48 s
100 Kolaka72 196.53 86.86 R
101 Kolaka79 343.49 86.15 R
102 Kolaka94 256.4 83.82 s
103 Kolaka96 190.85 82.58 R
104 Kolaka98 206.04 83.99 R
105 Kolaka99 279.25 81.86 R
Abbreviations: R, resistant; s, sensitive.
Table S1 (Continued)
(Continued)
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